8th Aug 2022 11:44
Ondine Biomedical Inc - Vancouver, Canada-based life sciences company focused on photodisinfection-based therapies - Recruits the final patient to its nasal photodisinfection exploratory phase two trial. The trial is evaluating how effectively Ondine's photodisinfection technology eradicates pathogens, specifically staphylococcus aureus, in the rose. The firm has recruited over 300 patients.
Chief Executive Carolyn Cross says: "Completing patient recruitment on this Phase II trial is an important step in our clinical development, and we look forward to being able to share the trial results in due course."
Current stock price: 38.50 pence, up 2.05 in London on Monday
12-month change: down 34%
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Ondine Biomed